Cohance Lifesciences

What Cohance Lifesciences does

Cohance Lifesciences (NSE/BSE: COHANCE) is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Hyderabad, India, operating 20+ manufacturing and R&D facilities across Telangana, Andhra Pradesh, and Gujarat in India, alongside a US subsidiary (NJ Bio Inc.) in Princeton, New Jersey. The platform is built around three core modalities — Antibody Drug Conjugates (ADCs), Nucleic Acid Chemistry (phosphoramidites, modified nucleosides, oligonucleotide synthesis), and Small Molecule APIs — with supporting service lines in Generic APIs, API+ & Formulations, Clinical & Analytical Services, and Specialty Chemicals (agrochemicals). Underlying technical capabilities include HPAPI containment handling at OEL down to ng/m³ levels, flow chemistry and continuous manufacturing reactors, multi-step synthesis at scale, and exatecan-derivative payload chemistry evidenced by US DMFs for S-Trione, SN-38, and Exatecan derivatives. The company is backed by private equity firm Advent International and holds regulatory filings across USFDA, EDQM, and PMDA, enabling commercial supply into the US, European, and Japanese pharmaceutical markets.

Revenue is generated through project-based B2B CDMO contracts — custom synthesis, process development, scale-up, and clinical/commercial supply — typically structured as multi-year, milestone-based agreements negotiated directly with clients via enterprise field sales. Pricing is bespoke and not publicly disclosed; engagements reflect long qualification cycles and sticky client relationships driven by regulatory re-validation costs. Customer segments center on global pharmaceutical and biotech companies (innovator and generic), global agrochemical companies, and a horizontal use-case segmentation around outsourced development and manufacturing. Cohance employs approximately 440+ R&D personnel including 200+ scientists and 100+ PhDs, with FY26 standalone quarterly revenue of Rs 805.09 crore and consolidated Q4 FY26 revenue of Rs 567.55 crore, the latter down 26.2% year-over-year amid USFDA Warning Letter pressure on the formulations business.

The company's strategic posture is defined by recent acquisitions of NJ Bio Inc. (December 2024) for ADC/bioconjugation US presence and Sapala Organics (October 2025) for nucleic acid chemistry depth, combined with a 2025 corporate rebranding from Suven Pharmaceuticals Limited to Cohance Lifesciences. A 2025-2026 leadership transition brought in former Cipla CEO Umang Vohra as Executive Chairman (May 1, 2026) and Group CEO (May 20, 2026) following the resignations of prior MD Dr. V. Prasada Raju and Executive Chairman Vivek Sharma, signaling a deliberate repositioning of the platform for the next CDMO growth cycle.

Name

Cohance Lifesciences

Legal name

Cohance Lifesciences Limited

Website

https://cohance.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Cohance Lifesciences is a Hyderabad-headquartered global CDMO providing multi-modality pharmaceutical manufacturing services — Antibody Drug Conjugates, nucleic acid chemistry, and small molecule APIs — to global pharmaceutical and biotech clients across more than 20 facilities in India and the United States.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract development manufacturing
• Pharmaceutical API manufacturing
• Antibody drug conjugates
• Nucleic acid therapeutics
• Small molecule synthesis

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Contract development and manufacturing organization providing custom synthesis, process development, and scale-up services for pharmaceutical and biotech clients across small molecules, ADCs, and nucleic acids. Revenue is project-based and contract-driven, typically structured as multi-year agreements with milestone-based payments. The model is characterized by high barriers to entry, long sales cycles, and sticky client relationships due to regulatory qualification requirements.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Cohance Lifesciences is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end services across Small Molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry from clinical phase through commercial supply. The company also manufactures Generic APIs and custom agrochemical intermediates, supported by 20+ facilities with 640+ KL reactor capacity and regulatory filings with USFDA, EDQM, and PMDA.

Product overview

Cohance Lifesciences is a technology-led, global CDMO (Contract Development and Manufacturing Organization) platform offering integrated pharmaceutical manufacturing services. The company operates as a unified multi-modality platform specialized in Small Molecule APIs, Antibody Drug Conjugates (ADCs), Nucleic Acid Chemistry, Generic APIs, and Specialty Chemicals (Agrochemicals). The portfolio includes end-to-end CDMO services with API+ & Formulations and Clinical & Analytical Services. The company has expanded through acquisitions including NJ Bio Inc. (US-based ADC and bioconjugation capabilities) and Sapala Organics (nucleic acid chemistry expertise). With 20+ manufacturing and R&D facilities across India and the US, the platform supports customers from discovery through commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecule API End-to-end CDMO services for small molecule active pharmaceutical ingredients (APIs), including development and manufacturing from lab to commercial scale, for global pharmaceutical and biotech innovators.
• Antibody Drug Conjugates (ADCs) Integrated CRDMO capabilities for antibody-drug conjugates covering discovery to commercial scale manufacturing, including ADC payloads and bioconjugation services, for global pharma/biotech innovators.
• Nucleic Acid Chemistry Capabilities in phosphoramidite chemistry, nucleoside modification, and oligonucleotide synthesis supporting therapeutic applications for nucleic acid-based therapeutics developers.
• Generic APIs Manufacturing and supply of generic active pharmaceutical ingredients and intermediates for global pharmaceutical markets.
• Specialty Chemicals (Agrochemicals) Custom development and manufacturing of agrochemical intermediates and active ingredients, including complex chemistries and hydrogenation capabilities, for global agrochemical companies.
• CDMO Services Contract development and manufacturing organization services including clinical and analytical services, process development, and scale-up support.
• API+ & Formulations Integrated API manufacturing combined with finished dosage formulation development and manufacturing capabilities.
• Clinical & Analytical Services High-class clinical solutions for bioavailability and bioequivalence studies with comprehensive analytical testing capabilities.

Quantifiable outcome

• Multiple US DMF filings for key compounds (S-Trione, SN-38, Exatecan derivative) demonstrating regulatory compliance and market access capability.
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Sapala OrganicscoreStrategic or Co-development PartnerSapala Organics was acquired by Cohance Lifesciences, expanding its capabilities and capacity in specialized chemistry. The acquisition strengthened Cohance's integrated CDMO platform by adding complementary synthesis capabilities and scientific talent to the existing multi-modality platform.
• NJ Bio Inc.coreTechnology or IntegrationNJ Bio Inc. is the US subsidiary of Cohance Lifesciences, providing US-based R&D, process development, and customer engagement capabilities. Located in New Jersey, it serves as the company's primary interface with North American pharmaceutical and biotech clients, offering proximity to the US market, regulatory expertise for USFDA filings, and collaborative drug development services.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Piramal Pharma Solutions: India-headquartered CDMO offering integrated drug substance, drug product, and biologics services including ADC capabilities — directly comparable multi-modality Indian CDMO competitor to Cohance.
• Syngene International: Indian CRO/CDMO with end-to-end discovery, development, and manufacturing services for small and large molecules, serving global pharma and biotech clients with similar multi-modality breadth.
• Laurus Labs: Indian CDMO/API manufacturer specializing in small-molecule APIs, custom synthesis, and formulations — a direct peer in API CDMO services with comparable scale and global customer base.
• Divis Laboratories: India-headquartered API and intermediates manufacturer with custom synthesis and contract manufacturing services targeting regulated markets — competing with Cohance's small molecule platform.
• Sai Life Sciences: India-based CDMO offering small molecule API development, HPAPI handling, and end-to-end contract manufacturing services — closely comparable in capability profile, scale, and customer target.

Broad incumbents

• Lonza Group: Global, large-scale CDMO providing small molecule, biologics, and cell & gene therapy services across the entire pharma value chain — a broad incumbent comparator against Cohance's ambitions.
• Catalent (Novo Holdings): Global CDMO with deep expertise in biologics, softgel, and oral dose development including ADC and gene therapy capabilities — establishes the upper-bound benchmark for an integrated CDMO platform.
• WuXi STA: WuXi AppTec's CDMO arm providing end-to-end small molecule and oligonucleotide development and manufacturing — a global CDMO competitor with overlapping small molecule and nucleic acid chemistry capabilities.
• Samsung Biologics: Global biologics CDMO offering large-scale mammalian protein and ADC manufacturing — comparable for ADC payload/bioconjugation contracts and commercial-scale biologics supply.

Regional players

• Biocon: Indian biopharmaceutical company with biologics manufacturing and CDMO services, competing for innovator clients in adjacent small molecule and biologics outsourcing segments from a similar India base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@CohanceLifesciences
• LinkedInlinkedin.com/company/cohance-lifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cohance Lifesciences